Raiffeisen Bank International AG purchased a new stake in Humana Inc. (NYSE:HUM - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 7,686 shares of the insurance provider's stock, valued at approximately $1,954,000.
A number of other large investors have also added to or reduced their stakes in HUM. FPC Investment Advisory Inc. acquired a new stake in shares of Humana during the 4th quarter worth about $27,000. Centricity Wealth Management LLC acquired a new stake in Humana during the fourth quarter worth approximately $30,000. LFA Lugano Financial Advisors SA boosted its holdings in shares of Humana by 56.3% during the fourth quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider's stock worth $32,000 after acquiring an additional 45 shares during the period. OFI Invest Asset Management bought a new stake in shares of Humana during the fourth quarter worth approximately $33,000. Finally, Transce3nd LLC acquired a new position in shares of Humana in the fourth quarter valued at approximately $38,000. Institutional investors own 92.38% of the company's stock.
Wall Street Analysts Forecast Growth
HUM has been the topic of several recent research reports. Morgan Stanley lowered their price objective on Humana from $301.00 to $285.00 and set an "equal weight" rating on the stock in a research report on Wednesday, February 12th. Oppenheimer lifted their target price on Humana from $300.00 to $310.00 and gave the stock an "outperform" rating in a report on Thursday, May 1st. Robert W. Baird lifted their target price on Humana from $270.00 to $300.00 and gave the stock a "neutral" rating in a report on Tuesday, April 15th. JPMorgan Chase & Co. dropped their target price on Humana from $257.00 to $256.00 and set a "neutral" rating for the company in a report on Tuesday, February 18th. Finally, Truist Financial dropped their price target on shares of Humana from $325.00 to $305.00 and set a "hold" rating for the company in a research report on Monday, May 12th. Seventeen equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, Humana currently has a consensus rating of "Hold" and a consensus target price of $286.81.
Check Out Our Latest Research Report on HUM
Humana Price Performance
Shares of HUM traded up $7.89 during midday trading on Tuesday, hitting $255.23. The company's stock had a trading volume of 1,878,205 shares, compared to its average volume of 1,770,415. Humana Inc. has a one year low of $212.45 and a one year high of $406.46. The company's fifty day simple moving average is $262.90 and its two-hundred day simple moving average is $269.48. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. The stock has a market capitalization of $30.80 billion, a price-to-earnings ratio of 25.65, a price-to-earnings-growth ratio of 2.05 and a beta of 0.49.
Humana (NYSE:HUM - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share for the quarter, topping analysts' consensus estimates of $10.07 by $1.51. The business had revenue of $32.11 billion for the quarter, compared to analyst estimates of $32 billion. Humana had a return on equity of 11.70% and a net margin of 1.02%. Humana's quarterly revenue was up 8.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $7.23 EPS. As a group, equities analysts expect that Humana Inc. will post 16.47 earnings per share for the current fiscal year.
Humana Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be given a $0.885 dividend. This represents a $3.54 annualized dividend and a yield of 1.39%. The ex-dividend date is Friday, June 27th. Humana's dividend payout ratio (DPR) is currently 25.04%.
Humana Profile
(
Free Report)
Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Read More

Before you consider Humana, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humana wasn't on the list.
While Humana currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.